National Tribune
Saturday, 21 November 2026
Health

Insulin Resistance by Age 30 Quite Telling of Future Heart Health

Key Takeaways

- Researchers found a relationship between young-adulthood insulin resistance and later-life ASCVD risk in the CARDIA cohort.

- An estimated two-thirds of this association was mediated through the clustering of cardiometabolic risk factors in midlife.

- Findings suggest that early identification of insulin resistance has promise for preventing or delaying metabolic syndrome and ultimately long-term ASCVD risk.

Insulin resistance in young adulthood was a predictor of atherosclerotic cardiovascular disease (ASCVD) years down the line in middle age, according to a CARDIA cohort analysis.

There were more than 3,000 CARDIA participants who remained under observation and free of ASCVD through year 20 (when they were 38-50 years old), with one in four having shown insulin resistance at baseline (at age 18-30), reported a group led by Chuyue Wu, MD, PhD, of the UCLA Fielding School of Public Health in Los Angeles.

With repeated clinical assessments and long-term follow-up, these individuals with insulin resistance in early adulthood had a significantly higher risk of ASCVD events through year 35 of the study, when they were 53-65 years old (risk ratio [RR] 1.50, 95% CI 1.13-2.01).

"These findings have potential implications for early cardiovascular prevention by suggesting that IR [insulin resistance] in young adulthood may signal an adverse CKM [cardiovascular-kidney-metabolic] trajectory before conventional cardiometabolic risk factors become fully established," Wu and colleagues wrote in JACC: Advances.

Of note, fasting insulin is not routinely measured in clinical practice. In the study, insulin resistance was indirectly measured as a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) value at or above the 75th percentile (≥2.67) after a 12-hour fast -- which may not exactly correspond to the gold-standard method of using the hyperinsulinemic-euglycemic clamp.

The researchers also found that 63.4% of the insulin resistance-later ASCVD relationship was mediated by midlife metabolic syndrome at the year-20 mark (indirect RR 1.29, 95% CI 1.13-1.48).

"The substantial mediation through midlife MetS [metabolic syndrome] further identifies the clustering of abnormalities in adiposity, blood pressure, glucose, and lipids as a potentially important intermediate stage linking early IR to later ASCVD," Wu's group suggested. "These findings highlight midlife MetS as an important marker of adverse CKM progression among individuals with IR earlier in adulthood."

Study authors acknowledged that they had not tried to account for changes in metabolic syndrome status and its individual components before or after year 20. Residual confounding is also possible given the study's observational nature.

"Although the findings support closer cardiometabolic surveillance among young adults with IR, further research is needed to determine whether HOMA-IR improves risk prediction beyond routinely measured clinical factors, develop practical approaches for identifying IR when fasting insulin is unavailable, and test whether preventing or delaying progression to MetS reduces subsequent ASCVD risk," Wu and colleagues urged.

One interpretation of the results is that "insulin resistance may represent an early signal of an adverse cardiometabolic trajectory, whereas MetS may mark a subsequent stage of risk-factor clustering," according to an accompanying editorial by Amier Haidar, MD, MPH, of McGovern Medical School, University of Texas Health Science Center at Houston, and Leonardo Roever, MHS, PhD, of the Brazilian Evidence-Based Health Network in Uberlândia, Brazil.

"For current practice, the most important implication is therefore not a new laboratory test. It is a new sense of urgency," the duo stressed. "A young adult with progressively increasing abdominal adiposity, worsening blood pressure, rising triglycerides, and deteriorating glycemic measures should not need to accumulate multiple abnormalities before clinicians recognize the direction of travel."

"Young adulthood represents a particularly important and underused window for prevention," the duo asserted. "Young adulthood is therefore not a cardiovascular waiting room; it is a period when cardiometabolic trajectories are being established."

The study included 3,622 participants in CARDIA, a multicenter, population-based, prospective cohort study. Included in this analysis were those who were enrolled in 1985-1986 as young adults (mean age at baseline 25.0 years, 45% men, 47% Black) who remained free of ASCVD through year 20.

A person was deemed to have metabolic syndrome if they met three of these criteria: waist circumference ≥102 cm in men or ≥88 cm in women; triglycerides ≥150 mg/dL; HDL cholesterol <40 mg/dL in men or <50 mg/dL in women; systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or the use of antihypertensive medication; and fasting glucose ≥100 mg/dL or the use of glucose-lowering medication.

Over a median follow-up of 14 years after year 20, 3.9% of participants logged ASCVD events.

Originally reported by MedPage Today.